These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35300176)

  • 1. Frequency and Factors Associated With Adverse Events Among Multi-Drug Resistant Tuberculosis Patients in Pakistan: A Retrospective Study.
    Atif M; Ahmed W; Nouman Iqbal M; Ahmad N; Ahmad W; Malik I; Al-Worafi YM
    Front Med (Lausanne); 2021; 8():790718. PubMed ID: 35300176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.
    Atif M; Bashir A; Ahmad N; Fatima RK; Saba S; Scahill S
    BMC Infect Dis; 2017 Sep; 17(1):655. PubMed ID: 28962599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance patterns, treatment outcomes and factors affecting unfavourable treatment outcomes among extensively drug resistant tuberculosis patients in Pakistan; a multicentre record review.
    Atif M; Mukhtar S; Sarwar S; Naseem M; Malik I; Mushtaq A
    Saudi Pharm J; 2022 Apr; 30(4):462-469. PubMed ID: 35527826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes among multidrug-resistant TB patients in Bahawal Victoria Hospital, Bahawalpur, Pakistan: a retrospective record review.
    Atif M; Ahmad W; Ahmad N; Malik I; Sarwar S
    Trans R Soc Trop Med Hyg; 2020 Oct; 114(10):733-741. PubMed ID: 32556195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occurrence of adverse events in patient receiving community-based therapy for multidrug-resistant tuberculosis in Pakistan.
    Javaid A; Khan MA; Jan F; Rauf M; Khan MA; Basit A; Mehreen S
    Tuberk Toraks; 2018 Mar; 66(1):16-25. PubMed ID: 30020037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Adverse Drug Events, Their Risk Factors, and Management Among Patients Treated for Multidrug-Resistant TB: A Prospective Cohort Study From Pakistan.
    Khan FU; Khan A; Khan FU; Hayat K; Rehman AU; Chang J; Khalid W; Noor S; Khan A; Fang Y
    Front Pharmacol; 2022; 13():876955. PubMed ID: 35656303
    [No Abstract]   [Full Text] [Related]  

  • 7. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
    Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
    BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
    Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD
    PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
    Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
    Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis in China: An Ambispective Cohort Study.
    Zhang Y; Wu S; Xia Y; Wang N; Zhou L; Wang J; Fang R; Sun F; Chen M; Zhan S
    Med Sci Monit; 2017 May; 23():2348-2356. PubMed ID: 28520704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and treatment outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar, Pakistan.
    Khan MA; Mehreen S; Basit A; Khan RA; Jan F; Ullah I; Ihtesham M; Khan A; Ullah U; Javaid A
    Saudi Med J; 2015 Dec; 36(12):1463-71. PubMed ID: 26620989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: data from centres with high drug resistance.
    Jaber AAS; Ibrahim B
    BMC Infect Dis; 2019 May; 19(1):464. PubMed ID: 31126246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes of extrapulmonary tuberculosis in Bahawalpur, Pakistan; a record review.
    Atif M; Fatima R; Ahmad N; Babar ZU
    J Pharm Policy Pract; 2020; 13():35. PubMed ID: 32724657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency, management and impact of adverse events on treatment outcomes in patients with multidrug resistant tuberculosis in Balochistan, Pakistan.
    Rafique S; Ahmad N; Khan S; Khan A; Atif M; Wahid A; Khan A; Waheed H
    J Pharm Policy Pract; 2024; 17(1):2332878. PubMed ID: 38572376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and Management of Adverse Drug Reactions Among Drug-Resistant Tuberculosis Patients: Analysis From a Prospective Study.
    Massud A; Syed Sulaiman SA; Ahmad N; Shafqat M; Chiau Ming L; Khan AH
    Front Pharmacol; 2022; 13():883483. PubMed ID: 35747749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.
    Gualano G; Mencarini P; Musso M; Mosti S; Santangelo L; Murachelli S; Cannas A; Di Caro A; Navarra A; Goletti D; Girardi E; Palmieri F
    PLoS One; 2019; 14(2):e0212948. PubMed ID: 30817779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam.
    Hoa NB; Nhung NV; Khanh PH; Hai NV; Quyen BT
    BMC Res Notes; 2015 Dec; 8():809. PubMed ID: 26695761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnitude and Impacts of Adverse Events of Injectable Containing Shorter Regimen in Programmatic Management of Multi-Drug Resistant Tuberculosis in Ethiopia: A Retrospective Cohort Study.
    Achalu DL; Mohammed FG; Teferi M
    Ther Clin Risk Manag; 2023; 19():889-901. PubMed ID: 38023629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
    PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.